|
|
||||||||
B-Inducing Kinase Deficiency Results in the Development of a Subset of Regulatory T Cells, which Shows a Hyperproliferative Activity upon Glucocorticoid-Induced TNF Receptor Family-Related Gene Stimulation1
Department of Microbiology and Immunology, Dartmouth Medical School and the Norris Cotton Cancer Center, Lebanon, NH 03756
| Abstract |
|---|
|
|
|---|
B-inducing kinase (NIK) expression in thymic stroma is important for the normal production of Treg but not for its suppression capacity. In this report, we have shown that Treg from NIK-deficient mice display hyperproliferative activities upon GITR stimulation through an IL-2-independent mechanism. Furthermore, high dose IL-2, anti-CD28 stimulation, or GITR ligand-transduced bone marrow-derived dendritic cells used as APC (culture conditions which drive Treg proliferation in vitro) could not ablate this difference in proliferative activity between NIK-deficient and wild-type Treg. Additional experiments have shown NIK-deficient mice have a higher ratio of CD4+CD25+CD62Llow Treg both in thymus and periphery than their wild-type littermates. This CD62low subset is responsible for the hyperproliferative activity upon GITR stimulation. These data suggest a novel role of NIK in controlling the development and expansion of CD4+CD25+ regulatory T cells. | Introduction |
|---|
|
|
|---|
(11). Glucocorticoid-induced TNFR family-related gene (GITR), a member of the TNFR superfamily, was identified in 1997 (12). Mice deficient of this molecule showed no significant developmental or immunological defects (13). GITR is expressed on activated T cells and constitutively expressed at high levels on Treg. Initially, it was reported that the engagement of GITR on Treg extinguished Treg activities (14, 15). Subsequent studies suggested that GITR signaling resulted in not only counteracting Treg suppressive activities but also providing costimulatory signals to both effector and Treg populations (16, 17, 18).
NF-
B-inducing kinase (NIK), a serine-threonine kinase, which phosphorylates both I
B kinase (IKK)
and IKK
, plays an integral part of the NF-
B signaling pathway (19, 20). NIK-deficient mice, as well as alymphoplasia (aly) mice, a natural strain with a mutated NIK, have abnormalities in the structural development of lymphoid organs and humoral immunity. Despite the disturbed thymic structure in these mice, the T cell compartment remains relatively normal. The CD4-CD8 T cell ratio and absolute cell numbers showed no significant alterations in both thymus and spleen (21, 22). Although predisposed to immunodeficiency, these mice develop autoimmune syndromes such as chronic inflammation in liver, pancreas, lung, salivary gland, and lacrimal gland by an unknown mechanism (23). Interestingly, a recent study has shown that the expression of mutant NIK in thymic stroma resulted in a reduced number of Treg. Although reduced in number, the remaining Treg had normal suppressive capacity suggesting a role of NIK in the establishment of central tolerance through control of Treg production (24).
The analysis presented herein of Treg subsets in NIK-deficient mice reveals impairment in Treg differentiation. We show that Treg from NIK-deficient mice display a hyperproliferative response upon GITR stimulation. This hyperproliferative response is not mediated by IL-2. Additionally, culture conditions that generally boost Treg proliferation, such as high concentrations of IL-2, anti-CD28 stimulation, or use of GITR ligand (GITRL)-transduced bone marrow-derived dendritic cells (BMDC) as APC, could not ablate this altered proliferative activity. Finally, we show an increased proportion of CD4+CD25+CD62Llow cells in NIK-deficient mice, and it is this Treg subset that is hyperproliferative to GITR signaling. The significance of this findings and their association to the autoimmunity in NIK-deficient mice is discussed.
| Materials and Methods |
|---|
|
|
|---|
NIK/ mice on a 129Sv/Ev background were kindly provided by Dr. R. D. Schreiber (Washington University, St. Louis, MO) (25). In all the experiments, NIK+/ mice were used as control. All mice were maintained by heterozygote mating in a pathogen-free facility.
Abs and reagents
mAb DTA-1 to mouse GITR was kindly provided by S. Sakaguchi (Kyoto University, Kyoto, Japan). mAb YGL386 to mouse GITRL was kindly provided by H. Waldmann (University of Oxford, Oxford, U.K.). FITC-conjugated anti-CD4 and anti-CD8, Cychrome-conjugated anti-CD4, PE-conjugated anti-CD25, allophycocyanin-conjugated anti-CD62L, PerCP-conjugated streptavidin were purchased from BD Pharmingen. Biotinylated anti-CD28, anti-CD44, anti-CD45RB, anti-CD69, anti-CD103, anti-CD152, anti-CD154, and FITC-conjugated anti-Foxp3 were purchased from ebioscience. CFSE was obtained from Molecular Probes. Recombinant murine GM-CSF, IL-2, and IL-4 was purchased from PeproTech.
Lymphocyte purification and proliferation assays
Single-cell suspensions were prepared from 8- to 10-wk-old mice and CD4+CD25 and CD4+CD25+ T cell subsets were purified by magnetic separation according to the manufacturers instructions (Miltenyi Biotec). Enriched cell populations and purified cells were phenotypically analyzed by FACS. The purities of CD4+CD25 and CD4+CD25+ T cells were >9095% respectively. For [3H]TdR incorporation assays, 5 x 104 CD4+CD25 and/or the indicated number of CD4+CD25+ T cells were cocultured with irradiated T cell-depleted splenocytes (15 x 104) as APCs and 5 µg/ml anti-CD3 (2C11) in 96-well U-bottom plates treated with anti-GITR Abs (10 µg/ml) or rat Ig as a control for 72 h at 37°C. Cultures were pulsed with [3H]TdR for the last 8 h of culture. For some experiments, plates precoated with 1 µg/ml anti-CD3 and 10 µg/ml anti-CD28 for 1 h at 37°C were used. For ex vivo cytoplasmic dye dilution assay, purified CD4+CD25+ T cells were CFSE-labeled (5 µM) and cultured as above. After 72 h incubation, cells were harvested and analyzed.
BMDC preparation and lentiviral transduction
Murine GITRL (isolated from the RAW 264.7 macrophage cell line) was cloned into lentiviral transfer vector pWPT (generously provided by the Trono Laboratory, University of Geneva, Geneva, Switzerland) using BamHI and SalI restriction sites (26). For lentivirus production, we cotransfected pWPT vector, and third-generation packaging vectors (encoding gag/pol, VSV-G, and rev) into 293FT cells (Invitrogen Life Technologies) and collected culture supernatants after 48 and 72 h of incubation at 37°C, 5% CO2. We recovered virus by ultracentrifugation (1.5 h at 25,000 rpm in a Beckman SW28 rotor) and resuspended the virus pellet in 25 µl of Opti-MEM media (Invitrogen Life Technologies). Viral titers were determined by serial dilution of concentrated lentivirus on 293FT cells followed by flow cytometry analysis after 48 h. Typical viral preparations yielded 5 x 108 transducing units (TU)/ml. We determined GFP or GITRL expression in transducted cells by flow cytometry 48 h posttransduction. Biotinylated anti-GITRL was used at a 1/200 dilution and then counterstained with streptavidin-allophycocyanin at 1/400.
For BMDC transduction, single-cell suspensions of bone marrow aspirates were ammonia chloride Tris buffer treated. Cells were then incubated for 7 days in complete RPMI 1640 supplemented with 10 ng/ml GM-CSF and 20 ng/ml IL-4. Media were changed with fresh cytokines at days 3 and 5. On day 5, cells received either control (GFP) or GITRL lentivirus at a multiplicity of infection (MOI) of 20 and allowed to incubate overnight. Polybrene was used to facilitate lentiviral transduction (8 µg/ml; Sigma-Aldrich). On day 7, cells were harvested, washed, counted, and applied to FACS to confirm gene expression. Indicated cell numbers were cultured and used as APCs in proliferation and suppression assays as previously described (27).
Cytokine secretion assays
ELISA was performed to assess the secretion of IL-2 under the same culture conditions used for the proliferation assays described above. Supernatants were collected at the indicated times. IL-2 was quantified according to the manufacturers instructions (BD Pharmingen).
Cell sorting
CD4+ T cells from NIK-deficient mice were first purified by MACS columns and then labeled with FITC-conjugated anti-CD4, PE-conjugated anti-CD25, and allophycocyanin-conjugated anti-CD62L. Enriched CD4+ T cells were then used for cell sorting. The purities of postsorted CD4+CD25+CD62Lhigh and CD4+CD25+CD62Llow populations were >95%. These cells were used for [3H]TdR incorporation assay as described.
Statistical analysis
Analysis of proliferation assays between the various treatments were analyzed by the two-tailed, paired Student t test. Values of p < 0.05 were considered significant.
| Results |
|---|
|
|
|---|
A recent paper has shown that there is a reduced frequency of Treg in the alymphoplasia mouse (Aly), a strain of mouse with a natural mutation of the NIK gene. While reduced numbers of Treg were observed, the Aly/Aly Treg retained their normal suppressive capacity in vitro on a per cell basis (24). Because NIK defect results in the absence of lymph node, we have determined the percentage of Treg in thymus and in spleen. Consistent with this finding, Fig. 1A illustrates that mice in which NIK has been deleted (NIK/) have a 5075% reduction in the ratio of CD4+CD25+ cells to total CD4 single-positive thymocytes or CD4+ T cells from spleen. Phenotypic analysis of Treg from NIK+/ or NIK/ mice show similar CD28, CD44, CD103, and GITR expression patterns in either a resting or an activated state (Fig. 1B). However, the expression of CD45RB, CD62L, and CD69 were distinctive in NIK/ Treg when compared with the expression pattern in NIK+/. In contrast to the Treg from NIK/ mice, the majority of NIK+/ Treg were CD45RBhigh, CD62Lhigh but CD69low. We then asked whether the quantitative and phenotypic differences between Treg from NIK+/ or NIK/ would change their regulatory function. As shown in Fig. 1C, the suppressive activity of Treg isolated from either NIK+/ or NIK/ mice are indistinguishable, as measured by a standard in vitro suppressor assay with different ratios of CD4+CD25/CD4+CD25+ T cells. Taken together, NIK-deficient mice, like NIK mutant mice, have a reduced number of Treg with comparable suppression activities.
|
Previous studies have shown that GITR signaling not only ablates Treg-mediated suppression, but also provides costimulatory signals to both effector and Treg populations (16, 17, 18). Because NIK plays a central role in the signaling of many TNFR family members, the role of NIK deficiency in GITR-induced Treg costimulation and suppressive activities was evaluated.
NIK function is not involved in GITR expression as both Treg from NIK+/ and NIK/ mice express similar levels of GITR (Fig. 1B). Furthermore, anti-CD3 induction of GITR on CD4+CD25 T cells was identical in both strains of mice (data not shown). To investigate the potential functional involvement of NIK in GITR signaling, anti-GITR-induced ablation of Treg suppression was evaluated. As shown in Fig. 2A, Teff proliferation was suppressed by both NIK+/ and NIK/ Treg in a standard suppression assay. Treg from NIK/ mice retained normal suppressive activity and suppression was extinguished upon GITR stimulation. Treg from NIK+/ mice were anergized or hypoproliferative to GITR activation in vitro as has been previously shown for wild-type (WT) Treg. In contrast, Treg from NIK/ mice proliferated in response to GITR stimulation (Fig. 2A) (14). To confirm Treg proliferation, we purified and CFSE labeled Treg from either NIK+/ or NIK/ mice and then cocultured with T cell-depleted splenocytes (APCs) for three days with or without GITR stimulation. Only Treg from NIK/ mice proliferated vigorously in response to GITR activation (Fig. 2B). Moreover, these GITR-mediated hyperproliferative activities were consistent even when the lower concentrations of anti-GITR were used (Fig. 2C). These results demonstrate that NIK/ Treg have distinctive characteristics from NIK+/ Treg, in that they display a hyperproliferative response upon GITR stimulation while their suppressive capacities remain intact.
|
Given that exogenous IL-2 can break Treg anergy in vitro (28, 29), it is possible that Treg from NIK-deficient mice produce high levels of IL-2 upon GITR activation to facilitate Treg proliferation. IL-2 production from anti-CD3 activated, NIK+/ and NIK/ CD4+CD25 and CD4+CD25+ T cells was measured. As reported in previous studies using Aly mice (21), CD4+CD25 Teff cells have reduced capacity to produce IL-2 in NIK/ mice in comparison to NIK+/ cells upon anti-CD3 activation. Interestingly, signaling through GITR further increased the IL-2 secretion in both groups (Fig. 3A). As for the CD4+CD25+ population, results were also consistent with previous studies that demonstrate undetectable levels of IL-2 production in both NIK/ and control cultures (Fig. 3A) (28, 29).
|
Enhanced proliferation by NIK/ Treg is induced by GITRL-transduced BMDC
To confirm that engagement of GITR on NIK/ Treg results in enhanced proliferation, GITRL was overexpressed on DCs and the proliferation of Treg from WT and NIK/ mice were evaluated. A lentiviral construct containing a full length GITRL sequence was used to transduce BMDC. The expression levels of GITRL were confirmed by FACS (data not shown). These transduced BMDC were then used as APCs. It is known that in the presence of anti-CD3, DCs can induce the proliferation of Treg in the absence of added cytokines. This phenomenon is believed to be dependent upon B7 costimulation by DCs (30). Consistent with this finding, BMDCs transduced with GFP control virus induced Treg proliferation from both groups (Fig. 4A). However, overexpression of GITRL resulted in enhanced proliferation of Treg from NIK/ mice but not Treg from WT mice. Although GITRL expression was significantly higher after transduction, to rule out the interference of endogenous GITRL expressed by BMDCs, similar results were obtained by using an APC-free system with plate-bound anti-CD3/anti-CD28 plus or minus anti-GITR stimulation (Fig. 4B). These results agree with previous data showing the enhanced proliferation of NIK/ Treg compared with WT Treg upon GITR activation.
|
CD62L (L-selectin) has been used to discriminate different subsets of Treg (31, 32, 33). Both CD4+CD25+CD62Lhigh and CD4+CD25+CD62Llow T cells have shown to be suppressive in vitro (32, 34). However, in vivo studies have indicated that only the CD62Lhigh Treg subset and not CD62Llow Treg is suppressive (31, 33). As mentioned earlier, analysis of the Treg populations in NIK/ vs NIK+/ revealed a marked reduction of the CD62Lhigh population in NIK/ mice. In thymus,
50% of the CD4 single-positive and CD25-positive thymocytes from NIK+/ mice were CD62Lhigh, whereas only 36% of the Treg from NIK/ mice expressed that phenotype. In spleen, over 75% of the Treg from NIK+/ mice were CD62Lhigh, whereas only 50% of the Treg from NIK/ mice shared that phenotype (Fig. 5A). To evaluate whether both the CD62Lhigh and CD62Llow subsets from the NIK/ were hyperproliferative in response to GITR engagement, the CD62Lhigh and CD62Llow populations were sorted and cultured with anti-CD3 and either anti-GITR or rat Ig as control (Fig. 5A). Interestingly, we found that only the CD62Llow but not CD62Lhigh subset from NIK/ mice was hyperresponsive upon GITR stimulation (Fig. 5B). Although there was a marked difference in the ability of GITR engagement to induce proliferation in the two subsets, both populations were suppressive and Foxp3 positive, in agreement with previous studies (Fig. 5, C and D).
|
| Discussion |
|---|
|
|
|---|
It is known that Treg are anergic in vitro, but can proliferate upon Ag immunization in vivo (35, 36). In addition to signaling via the TCR, activation through a number of costimulatory molecules such as CD28/B7, 4-1BB/4-1BBL, OX40/OX40L, and GITR/GITRL also regulate Treg anergy and proliferation (18, 37, 38, 39). In this study, we show that Treg from NIK/ mice were hyperproliferative to GITR triggering. Like other TNFR family members, GITR recruits several different TNFR-associated factors to its cytoplasmic tail after engagement of its ligand. GITR signals via these adaptor proteins to mediate the activation of multiple signaling pathways including NIK/NF
B and ERK, which in turn phosphorylate and activate downstream transcription factors (17, 40, 41). It appears that NIK tempers the signaling via GITR, such that in its absence, signaling through GITR induces greater levels of proliferation. These observations may be explained by a recent study by Wallach et al. (42) in studies of CD27 signaling (42, 43). These investigators suggested a possible functional role of interaction between NIK and Siva, a proapoptotic protein, which binds to the CD27 cytoplasmic tail after CD70 engagement (42, 43). Interestingly, GITR, like CD27, recruits Siva upon stimulation and it has been shown that GITR and Siva interaction induced apoptosis (44). It is possible that in the absence of NIK, Siva may not be recruited to the GITR tail, and may result in heightened T cell proliferation.
Both IL-2 and CD28 trigger Treg expansion and function. Previous studies have shown that either by adding IL-2 or providing costimulatory signals through anti-CD28 or mature BMDCs, the anergic state of Treg in vitro could be broken (28, 29, 30, 32). It could be argued that heightened IL-2 production by NIK/ Treg is the basis for GITR-induced hyperproliferation. However, the difference in proliferative activity between NIK/ and WT Treg was not altered upon the addition IL-2. Moreover, Treg from NIK/ mice produced little or undetectable IL-2 when triggered through GITR. These data are consistent with the hypothesis that there is an intrinsic defect in NIK/ Treg that results in heightened signaling via GITR.
The involvement of NIK in a wide spectrum of signaling pathways in many different cell types has made it extremely difficult to clearly delineate the basic mechanisms responsible for autoimmunity in NIK-deficient mice. Among the potential consequences of NIK deficiency, dysregulation of AIRE (autoimmune regulator) in NIK/ mice may play an important role. AIRE has been shown to be a key mediator in the establishment of central tolerance by regulating ectopic expression of tissue-specific Ags in thymus (45). Lymphotoxin-
receptor deficiency or the mutation of its downstream signaling component, NIK, results in the failure of AIRE induction in the thymus that would ultimately lead to impaired clonal deletion (24, 46). Moreover, although there was no qualitative or quantitative alteration of Treg in AIRE-deficient mice (47), the development of autoimmunity in NIK-deficient/mutant mice may result from the impaired development of Treg in these mice, Kajiura et al. (24) have shown that abnormal NIK expression in the thymic environment resulted in the poor production of Treg. Furthermore, the autoimmune symptoms from mice grafted with a NIK-deficient thymus could be rescued simply by adoptive transfer of more Treg. In our experiments, we have also noted a lower frequency of Treg in NIK-deficient mice.
In addition to the reduced overall numbers of Treg in NIK-deficient mice, we have also shown a disruption in the development of Treg subsets. Treg have been shown to be functionally and phenotypically heterogenous, based in part on the expression of CD62L (31, 33, 48). Previous studies have shown in both a diabetes model and a graft vs host disease model, only the CD62Lhigh but not CD62Llow subset could delay disease or prevent graft rejection (31, 33). This phenomenon has been attributed to the different abilities of Treg to home to lymph nodes to suppress early events in alloantigen-specific T cell activation (31). In other models, such as autoimmune gastritis and colitis, when the suppression of early T cell priming was not required, both CD62Lhigh and CD62Llow subsets functioned equally in the prevention of autoimmunity (48). In NIK-deficient mice, we have found a substantial reduction in the percentage of CD62Lhigh Treg subset in both thymus and spleen compared with their WT littermates. Additional experiments have shown that CD62Llow Treg in NIK-deficient mice was the population that exhibited the hyperproliferative activity in response to GITR stimulation. Taken together, the enhanced discrepancy in population size of CD62Lhigh and CD62Llow Treg in thymus (50% vs 36% CD62Lhigh) and in spleen (75 vs 50% CD62Lhigh) between NIK+/ and NIK/ mice, respectively, implicate NIK involvement in early Treg subset differentiation in thymus and a continuing skewing in the periphery. Moreover, the pre-existing higher percentage of the CD62Llow population in thymus of NIK/ mice is in agreement with our in vitro suppression assay results, suggesting these cells belong to a specific Treg lineage, and do not simply represent preactivated conventional T cells.
The involvement of NIK in the development of autoimmunity is complex, impacting different cell types and different signaling pathways. Taken together, our studies and those published illustrate that NIK deficiency results in the escape of autoreactive T cells to the periphery due to impaired AIRE expression. To compound the impact of heightened peripheral autoreactive T cell activities, NIK deficiency results in the reduced development of Treg, and a skewing of the Treg population from CD62Lhigh to CD62low resulting in a less efficient and vigorous regulatory T cell response. Moreover, GITR signaling in the periphery would further aggravate the imbalance of CD62Lhigh and CD62Llow subsets leading to autoimmunity (Fig. 6).
|
| Acknowledgments |
|---|
| Disclosures |
|---|
|
|
|---|
| Footnotes |
|---|
1 This work was supported by National Institutes of Health Grants CA91436-01. ![]()
2 Address correspondence and reprint requests to Dr. Randolph J. Noelle, Department of Microbiology and Immunology, Norris Cotton Cancer Center, Dartmouth Hitchcock Medical Center, Dartmouth Medical School, 1 Medical Center Drive, Lebanon, NH, 03756. E-mail address: rjn{at}dartmouth.edu ![]()
3 Abbreviations used in this paper: Treg, regulatory T cell; Teff, effector T cell; NIK, NF-
B-inducing kinase; GITR, glucocorticoid-induced TNFR family-related gene; IKK, I
B kinase; BMDC, bone marrow-derived dendritic cell; GITRL, GITR ligand; TU, transducing unit; MOI, multiplicity of infection; WT, wild type; AIRE, autoimmune regulator. ![]()
Received for publication January 20, 2005. Accepted for publication May 23, 2005.
| References |
|---|
|
|
|---|
-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.[Abstract]
B induction by TNF, CD95 and IL-1. Nature 385: 540-544.[Medline]
B kinase
and
by two upstream kinases, NF-
B-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc. Natl. Acad. Sci. USA 95: 3537-3542.
B-inducing kinase. J. Immunol. 165: 804-812.
B-inducing kinase in T cell activation through the TCR/CD3 pathway. J. Immunol. 169: 1151-1158.
B-inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. J. Immunol. 172: 2067-2075.
receptor-induced NF-
B transcriptional activity in NIK-deficient mice. Science 291: 2162-2165.
B activation pathways by NF-
B-inducing kinase. Immunity 21: 477-489.[Medline]
This article has been cited by other articles:
![]() |
W. Jin, X.-F. Zhou, J. Yu, X. Cheng, and S.-C. Sun Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK Blood, June 25, 2009; 113(26): 6603 - 6610. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Li, N. Perez, S. Karumuthil-Melethil, B. S. Prabhakar, M. J. Holterman, and C. Vasu Enhanced Engagement of CTLA-4 Induces Antigen-Specific CD4+CD25+Foxp3+ and CD4+CD25 TGF-beta1+ Adaptive Regulatory T Cells J. Immunol., October 15, 2007; 179(8): 5191 - 5203. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. W. Tas, M. J. Vervoordeldonk, N. Hajji, J. H. N. Schuitemaker, K. F. van der Sluijs, M. J. May, S. Ghosh, M. L. Kapsenberg, P. P. Tak, and E. C. de Jong Noncanonical NF-{kappa}B signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) induction and immune regulation Blood, September 1, 2007; 110(5): 1540 - 1549. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Kapp, K. Honjo, L. M. Kapp, X. y. Xu, A. Cozier, and R. P. Bucy TCR transgenic CD8+ T cells activated in the presence of TGF{beta} express FoxP3 and mediate linked suppression of primary immune responses and cardiac allograft rejection Int. Immunol., November 1, 2006; 18(11): 1549 - 1562. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |